NIAID: Broadly neutralising Abs key to HIV vaccine
Development of a successful HIV vaccine will rely on broadly neutralising antibodies (bNAbs), says the Director of the National Institute of Allergy and Infectious Diseases.
Archives for August 3, 2015
TxCell: we’ll continue to use CMO even after we get back our GMP
French biotech TxCell is outsourcing manufacture of its T-cell therapy Ovasave to MaSTherCell, and says it expects to regain GMP certification of its own site later this year.
NeuroFx signs up Cytovance to develop, manufacture stem cell-derived stroke therapy
Oklahoma-based contract development and manufacturer Cytovance Biologics has teamed up with NeuroFx to develop and manufacture a stem cell derived, cell-free therapy for neurological conditions.